Sickle Cell Disease (SCD) is a genetic disorder causing red blood cells to be stiff and sickle-shaped. This can lead to various health issues, including pain crises and organ damage. In pregnant women, SCD can result in complications like high blood pressure and preterm delivery. This study aims to see if regular red blood cell (RBC) transfusions can reduce the number of these problems during pregnancy, compared to usual care. RBC transfusion involves giving a patient blood that matches their own type to help manage their disease.
The study will include pregnant women with SCD, who are between 6 to 20 weeks pregnant. They will receive either regular RBC transfusions or standard care for about 8-10 months, including 2 months after birth.
- Study duration is approximately 8-10 months.
- Participants are randomly assigned to treatment groups.
- Eligibility requires informed consent and insurance approval for transfusions.
How understandable was the trial content above?
Hard to understand
Easy to understand